Skip to main content
Top
Published in: Clinical and Experimental Nephrology 6/2013

01-12-2013 | Original Article

Long-term observations of clinicopathological characteristics and outcome of Japanese patients with pauci-immune crescentic glomerulonephritis

Authors: Kiyoki Kitagawa, Kengo Furuichi, Yasuyuki Shinozaki, Tadashi Toyama, Shinji Kitajima, Akinori Hara, Yasunori Iwata, Norihiko Sakai, Shuichi Kaneko, Takashi Wada, Kanazawa Study Group for Renal Diseases and Hypertension

Published in: Clinical and Experimental Nephrology | Issue 6/2013

Login to get access

Abstract

Background

The clinicopathological characteristics and outcome with pauci-immune crescentic glomerulonephritis (CreGN) are presumed to vary over time. We examined the characteristics and outcome of Japanese patients with CreGN according to the treatment periods.

Patients and methods

From 1968 to 2011, we examined a total of 102 patients diagnosed with pauci-immune CreGN by renal biopsy. The patients were divided into three groups according to the treatment periods—Group I (1968–1988, n = 18), Group II (1989–2001, n = 37; when the nationwide survey of rapidly progressive glomerulonephritis [RPGN] was performed in Japan), and Group III (2002–2011, n = 47; after publication of the Japanese guideline for RPGN).

Results

There were no significant differences in blood pressure, renal function or anti-neutrophil cytoplasmic antibody titer between groups. On the other hand, the rate of crescent formation and degree of interstitial inflammatory cell infiltration were decreased in Group III. Serum creatinine (<3.0, 3.0–6.0, ≥6.0 mg/dL) and crescent formation (<30, 30–50, 50–80, ≥80 %) were significant renal prognostic factors in Group III [serum creatinine: hazard ratio (HR) 4.79, 95 % confidence interval (CI) 1.43–16.1, P = 0.011; crescent formation: HR 2.86, 95 % CI 1.06–7.73, P = 0.039]. Furthermore, renal survival rate of patients with crescent formation <50 % and patient survival rate of patients with serum creatinine <3 mg/dL were improved in Group III.

Conclusion

Patients with CreGN were diagnosed in the early phase of crescent formation and outcome has improved in recent years.
Literature
1.
go back to reference Churg J, Bernstein J, Glassock RJ, editors. Classification of glomerular disease. Renal disease: classification and atlas of glomerular diseases. 2nd ed. New York: Igaku-shoin Medical; 1995. p. 11. Churg J, Bernstein J, Glassock RJ, editors. Classification of glomerular disease. Renal disease: classification and atlas of glomerular diseases. 2nd ed. New York: Igaku-shoin Medical; 1995. p. 11.
2.
go back to reference Koyama A, Yamagata K, Makino H, Arimura Y, Wada T, Nitta K, et al. A nationwide survey of rapidly progressive glomerulonephritis in Japan: etiology, prognosis and treatment diversity. Clin Exp Nephrol. 2009;13:633–50.PubMedCrossRef Koyama A, Yamagata K, Makino H, Arimura Y, Wada T, Nitta K, et al. A nationwide survey of rapidly progressive glomerulonephritis in Japan: etiology, prognosis and treatment diversity. Clin Exp Nephrol. 2009;13:633–50.PubMedCrossRef
3.
go back to reference Bajema IM, Hagen EC, Hermans J, Noël LH, Waldherr R, Ferrario F, et al. Kidney biopsy as a predictor for renal outcome in ANCA-associated necrotizing glomerulonephritis. Kidney Int. 1999;56:1751–8.PubMedCrossRef Bajema IM, Hagen EC, Hermans J, Noël LH, Waldherr R, Ferrario F, et al. Kidney biopsy as a predictor for renal outcome in ANCA-associated necrotizing glomerulonephritis. Kidney Int. 1999;56:1751–8.PubMedCrossRef
4.
go back to reference Hauer HA, Bajema IM, Van Houwelingen HC, Ferrario F, Noël LH, Waldherr R, et al. Determinants of outcome in ANCA-associated glomerulonephritis: a prospective clinico-histopathological analysis of 96 patients. Kidney Int. 2002;62:1732–42.PubMedCrossRef Hauer HA, Bajema IM, Van Houwelingen HC, Ferrario F, Noël LH, Waldherr R, et al. Determinants of outcome in ANCA-associated glomerulonephritis: a prospective clinico-histopathological analysis of 96 patients. Kidney Int. 2002;62:1732–42.PubMedCrossRef
5.
go back to reference de Lind van Wijngaarden RA, Hauer HA, Wolterbeek R, Jayne, Gaskin G, Rasmussen N, et al. Clinical and histologic determinants of renal outcome in ANCA-associated vasculitis: a prospective analysis of 100 patients with severe renal involvement. J Am Soc Nephrol. 2006;17:2264–74.PubMedCrossRef de Lind van Wijngaarden RA, Hauer HA, Wolterbeek R, Jayne, Gaskin G, Rasmussen N, et al. Clinical and histologic determinants of renal outcome in ANCA-associated vasculitis: a prospective analysis of 100 patients with severe renal involvement. J Am Soc Nephrol. 2006;17:2264–74.PubMedCrossRef
6.
go back to reference Berden AE, Ferrario F, Hagen EC, Jayne DR, Jennette JC, Joh K, et al. Histopathologic classification of ANCA-associated glomerulonephritis. J Am Soc Nephrol. 2010;21:1628–36.PubMedCrossRef Berden AE, Ferrario F, Hagen EC, Jayne DR, Jennette JC, Joh K, et al. Histopathologic classification of ANCA-associated glomerulonephritis. J Am Soc Nephrol. 2010;21:1628–36.PubMedCrossRef
7.
go back to reference Neumann I, Kain R, Regele H, Soleiman A, Kandutsch S, Meisl FT. Histological and clinical predictors of early and late renal outcome in ANCA-associated vasculitis. Nephrol Dial Transplant. 2005;20:96–104.PubMedCrossRef Neumann I, Kain R, Regele H, Soleiman A, Kandutsch S, Meisl FT. Histological and clinical predictors of early and late renal outcome in ANCA-associated vasculitis. Nephrol Dial Transplant. 2005;20:96–104.PubMedCrossRef
8.
go back to reference Takeda S, Kida H, Yokoyama H, Tomosugi N, Kobayashi K. Two distinct types of crescentic glomerulonephritis. Clin Nephrol. 1992;37:285–93.PubMed Takeda S, Kida H, Yokoyama H, Tomosugi N, Kobayashi K. Two distinct types of crescentic glomerulonephritis. Clin Nephrol. 1992;37:285–93.PubMed
9.
go back to reference Takeda S, Kida H, Yokoyama H, Takazakura E, Kobayashi K. Methylprednisolone pulse therapy in two clinical types of crescentic glomerulonephritis. Intern Med. 1998;37:585–91.PubMedCrossRef Takeda S, Kida H, Yokoyama H, Takazakura E, Kobayashi K. Methylprednisolone pulse therapy in two clinical types of crescentic glomerulonephritis. Intern Med. 1998;37:585–91.PubMedCrossRef
10.
go back to reference Ito-Ihara T, Ono T, Nogaki F, Suyama K, Tanaka M, Yonemoto S, et al. Clinical efficacy of intravenous immunoglobulin for patients with MPO-ANCA-associated rapidly progressive glomerulonephritis. Nephron Clin Pract. 2006;102:c35–42.PubMedCrossRef Ito-Ihara T, Ono T, Nogaki F, Suyama K, Tanaka M, Yonemoto S, et al. Clinical efficacy of intravenous immunoglobulin for patients with MPO-ANCA-associated rapidly progressive glomerulonephritis. Nephron Clin Pract. 2006;102:c35–42.PubMedCrossRef
11.
go back to reference Martinez V, Cohen P, Pagnoux C, Vinzio S, Mahr A, Mouthon L, et al. Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-two patients. Arthritis Rheum. 2008;58:308–17.PubMedCrossRef Martinez V, Cohen P, Pagnoux C, Vinzio S, Mahr A, Mouthon L, et al. Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-two patients. Arthritis Rheum. 2008;58:308–17.PubMedCrossRef
12.
go back to reference Jayne DR, Gaskin G, Rasmussen N, Abramowicz D, Ferrario F, Guillevin L, et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol. 2007;18:2180–8.PubMedCrossRef Jayne DR, Gaskin G, Rasmussen N, Abramowicz D, Ferrario F, Guillevin L, et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol. 2007;18:2180–8.PubMedCrossRef
13.
go back to reference Szpirt WM, Heaf JG, Petersen J. Plasma exchange for induction and cyclosporine A for maintenance of remission in Wegener’s granulomatosis—a clinical randomized controlled trial. Nephrol Dial Transplant. 2011;26:206–13.PubMedCrossRef Szpirt WM, Heaf JG, Petersen J. Plasma exchange for induction and cyclosporine A for maintenance of remission in Wegener’s granulomatosis—a clinical randomized controlled trial. Nephrol Dial Transplant. 2011;26:206–13.PubMedCrossRef
14.
go back to reference Hasegawa M, Ohashi A, Kabutan N, Hiramatsu S, Kato M, Murakami K, et al. Cytapheresis for the treatment of myeloperoxidase antineutrophil cytoplasmic autoantibody-associated vasculitis: a pilot study of 21 patients. Ther Apher Dial. 2006;10:412–8.PubMedCrossRef Hasegawa M, Ohashi A, Kabutan N, Hiramatsu S, Kato M, Murakami K, et al. Cytapheresis for the treatment of myeloperoxidase antineutrophil cytoplasmic autoantibody-associated vasculitis: a pilot study of 21 patients. Ther Apher Dial. 2006;10:412–8.PubMedCrossRef
15.
go back to reference Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, Dadoniené J, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med. 2003;349:36–44.PubMedCrossRef Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, Dadoniené J, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med. 2003;349:36–44.PubMedCrossRef
16.
go back to reference Pagnoux C, Mahr A, Hamidou MA, Boffa JJ, Ruivard M, Ducroix JP, et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med. 2008;359:2790–803.PubMedCrossRef Pagnoux C, Mahr A, Hamidou MA, Boffa JJ, Ruivard M, Ducroix JP, et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med. 2008;359:2790–803.PubMedCrossRef
17.
go back to reference Hirayama K, Kobayashi M, Hashimoto Y, Usui J, Shimizu Y, Hirayama A, et al. Treatment with the purine synthesis inhibitor mizoribine for ANCA-associated renal vasculitis. Am J Kidney Dis. 2004;44:57–63.PubMedCrossRef Hirayama K, Kobayashi M, Hashimoto Y, Usui J, Shimizu Y, Hirayama A, et al. Treatment with the purine synthesis inhibitor mizoribine for ANCA-associated renal vasculitis. Am J Kidney Dis. 2004;44:57–63.PubMedCrossRef
18.
go back to reference Jones RB, Ferraro AJ, Chaudhry AN, Brogan P, Salama AD, Smith KG, et al. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2009;60:2156–68.PubMedCrossRef Jones RB, Ferraro AJ, Chaudhry AN, Brogan P, Salama AD, Smith KG, et al. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2009;60:2156–68.PubMedCrossRef
19.
go back to reference Wada T, Hara A, Arimura Y, Sada KE, Makino H, Research Group of Intractable Vasculitis Ministry of Health, Labor and Welfare of Japan. Risk factors associated with relapse in Japanese patients with microscopic polyangiitis. J Rheumatol. 2012;39:545–51.PubMedCrossRef Wada T, Hara A, Arimura Y, Sada KE, Makino H, Research Group of Intractable Vasculitis Ministry of Health, Labor and Welfare of Japan. Risk factors associated with relapse in Japanese patients with microscopic polyangiitis. J Rheumatol. 2012;39:545–51.PubMedCrossRef
Metadata
Title
Long-term observations of clinicopathological characteristics and outcome of Japanese patients with pauci-immune crescentic glomerulonephritis
Authors
Kiyoki Kitagawa
Kengo Furuichi
Yasuyuki Shinozaki
Tadashi Toyama
Shinji Kitajima
Akinori Hara
Yasunori Iwata
Norihiko Sakai
Shuichi Kaneko
Takashi Wada
Kanazawa Study Group for Renal Diseases and Hypertension
Publication date
01-12-2013
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 6/2013
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-013-0798-4

Other articles of this Issue 6/2013

Clinical and Experimental Nephrology 6/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine